U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Enfuvirtide is a linear 36-amino acid synthetic peptide that inhibits the fusion of HIV-1 with CD4 cells. Enfuvirtide works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. Enfuvirtide interferes with the entry of HIV-1 into cells by inhibiting fusion of viral and cellular membranes. Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. Enfuvirtide is indicated for the treatment of HIV-1 infection, in combination therapy with other antiretrovirals, in patients where all other treatments have failed. Common adverse drug reactions associated with enfuvirtide therapy include: injection site reactions (pain, hardening of skin, erythema, nodules, cysts, itch; experienced by nearly all patients, particularly in the first week), peripheral neuropathy, insomnia, depression, cough, dyspnoea, anorexia, arthralgia, infections (including bacterial pneumonia) and/or eosinophilia.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FUZEON

Approved Use

FUZEON is an HIV-1 fusion inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment experienced patients with HIV-1 replication despite ongoing antiretroviral therapy.

Launch Date

1.0475136E12
PubMed

PubMed

TitleDatePubMed
New class of HIV drugs shows promise.
2001 Dec
T-20 small program, CD4 < 50, will enroll November 27 at 3:00 P.M.
2001 Oct 26
[T-20: a fusion inhibitor].
2002
Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.
2002 Aug 16
Enfuvirtide.
2002 Dec
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
2002 Dec 10
Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living.
2002 Jul
Gateways to Clinical Trials. June 2002.
2002 Jun
Thousands face loss of treatment in ADAP money crisis.
2002 Jun 28
A T-20 diary.
2002 Mar
9th National Retrovirus Conference: new treatments, new choices.
2002 May
Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design.
2002 Nov 29
Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid.
2002 Sep 12
Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.
2002 Sep 27
HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James.
2002 Sep 6
ConFuzeon reigns.
2003 Apr
Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
2003 Apr
David Reddy--taking HIV therapy to new frontiers. Interview by Pam Das.
2003 Feb
Anti-HIV drug updates--three drugs on the near horizon.
2003 Jan
Carbohydrate-centered maleimide cluster as a new type of templates for multivalent peptide assembling. synthesis of multivalent HIV-1 gp41 peptides.
2003 Jan 2
Synthesis of maleimide-activated carbohydrates as chemoselective tags for site-specific glycosylation of peptides and proteins.
2003 Jan-Feb
First fusion inhibitor for advanced HIV.
2003 Jul
Large-scale manufacture of peptide therapeutics by chemical synthesis.
2003 Jul
[HIV infections: further options for combination therapy].
2003 Jul 11
FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.
2003 Jun
Antiviral Research--16th Annual International Conference. Satellite symposium: clinical update on antiviral drugs. 27 April-1 May 2003, Savannah, GA, USA.
2003 Jun
Gateways to clinical trials.
2003 Jun
Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains.
2003 Jun 1
[First fusion inhibitor is available. No entry for HIV-1 viruses].
2003 Jun 19
Enfuvirtide (Fuzeon) for HIV Infection.
2003 Jun 23
Treatment with a new fusion inhibitor: patient issues with enfuvirtide (T-20). A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
2003 Mar
Clinical safety and efficacy of enfuvirtide (T-20), a new fusion inhibitor. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
2003 Mar
Gateways to clinical trials. March 2003.
2003 Mar
FUZEON (enfuvirtide, T-20). Breaking barriers or breaking the bank?
2003 Mar
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.
2003 Mar
New antiretroviral drugs.
2003 Mar
Fusion inhibitor approved.
2003 May
Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
2003 May
The optimal use of enfuvirtide.
2003 May
Enfuvirtide access, administration, and patient education.
2003 May
FDA news. Price criticized for new anti-HIV drug.
2003 May
Enfuvirtide, a new drug for HIV infection.
2003 May 10
Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants.
2003 May 2
Fusion inhibition--a major but costly step forward in the treatment of HIV-1.
2003 May 29
Novel therapies based on mechanisms of HIV-1 cell entry.
2003 May 29
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
2003 May 29
[HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients].
2003 May 9
New class of medications approved for advance HIV.
2003 May-Jun
Inhibiting HIV-1 entry with fusion inhibitors.
2003 Sep
Virus entry as a target for anti-HIV intervention.
2003 Sep

Sample Use Guides

Adults: Recommended dosage of Enfuvirtide is 90 mg (1 mL) twice daily injected subcutaneously into the upper arm, anterior thigh, or abdomen. Pediatric Patients (weighing at least 11kg): Recommended dose of 2 mg/kg twice daily up to a maximum dose of 90 mg twice daily injected subcutaneously.
Route of Administration: Other
Substance Class Protein
Created
by admin
on Sat Jun 26 18:16:10 UTC 2021
Edited
by admin
on Sat Jun 26 18:16:10 UTC 2021
Protein Sub Type
Sequence Type COMPLETE
Record UNII
19OWO1T3ZE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ENFUVIRTIDE
EMA EPAR   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
ENFUVIRTIDE [VANDF]
Common Name English
DP-178
Code English
T-20
Code English
FUZEON
Brand Name English
DP178
Code English
ENFUVIRTIDE [INN]
Common Name English
ENFUVIRTIDE [EMA EPAR]
Common Name English
ENFUVIRTIDE [USAN]
Common Name English
T20
Code English
ENFUVIRTIDE [MART.]
Common Name English
ENFUVIRTIDE [MI]
Common Name English
ENFUVIRTIDE [WHO-DD]
Common Name English
ENFUVIRTIDE [ORANGE BOOK]
Common Name English
ENFUVIRTIDE [HSDB]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175616
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
NCI_THESAURUS C1660
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
NDF-RT N0000175615
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
WHO-ATC J05AX07
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
WHO-VATC QJ05AX07
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
EMA ASSESSMENT REPORTS FUZEON (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
LIVERTOX 350
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
Code System Code Type Description
DRUG CENTRAL
1010
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
EVMPD
SUB12496MIG
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
CAS
159519-65-0
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
NCI_THESAURUS
C2105
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
EPA CompTox
159519-65-0
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
HSDB
7341
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
ChEMBL
CHEMBL525076
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
INN
8063
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
DRUG BANK
DB00109
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
RXCUI
139896
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M4906
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
ENFUVIRTIDE
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
LACTMED
Enfuvirtide
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
MESH
C105196
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
FDA UNII
19OWO1T3ZE
Created by admin on Sat Jun 26 18:16:10 UTC 2021 , Edited by admin on Sat Jun 26 18:16:10 UTC 2021
PRIMARY
Related Record Type Details
INHIBITOR->TARGET ORGANISM
TARGET -> INHIBITOR
Enfuvirtide binds to gp41 preventing the creation of an entry pore for the capsid of the virus, keeping it out of the cell.
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
Volume of Distribution PHARMACOKINETIC
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Biological Half-life PHARMACOKINETIC